The Committee for Medicinal Products for Human Use of the European Medicines Agency revealed a negative trend vote after their meeting with Puma Biotechnology Inc. (PBYI) regarding its breast cancer treatment neratinib.
from RTT - Before the Bell http://ift.tt/2nagLdC
via IFTTT
No comments:
Post a Comment